Xuanzhu Biopharmaceutical Co., Ltd. (XUANZHUBIO-B, stock code: 02575) made a spectacular debut on the Hong Kong Stock Exchange, with its shares soaring 163.79% in early trading on Wednesday. This remarkable surge reflects the strong investor appetite for the biopharmaceutical company and marks a successful initial public offering (IPO).

The company's shares opened at HK$29.46, significantly higher than its IPO price of HK$11.60 per share. This opening price represents a 154% premium over the offer price, indicating robust demand from investors. The global offering raised net proceeds of approximately HK$701 million (US$89.6 million) for the company, which it plans to use for research and development, expanding its product pipeline, and general corporate purposes.

The enthusiasm for XUANZHUBIO-B's shares was evident even before its market debut. The Hong Kong public offering portion was massively oversubscribed by 4,908.33 times, while the international offering received 10.15 times oversubscription. This overwhelming response led to the company allocating 10% of the total 67,333,500 H shares to the Hong Kong public offering, with the remaining 90% going to the international offering.

Analysts attribute the stock's strong performance to several factors, including the company's promising pipeline in the biopharmaceutical sector, the overall positive sentiment in the Hong Kong market towards innovative pharmaceutical concepts, and the scarcity of high-quality biotech listings. As the trading day progresses, market participants will be closely watching to see if XUANZHUBIO-B can maintain its impressive gains and what this successful listing might mean for future biotech IPOs in the region.